SMi Group reports: Astra Zeneca, Pfizer, Astex Pharmaceuticals, ZoBio and Chemical Computing Group will meet at the SMi’s 15th annual Advances and Progress in Drug Design Conference (15-16 February 2016, London, UK) to discuss identification of lead inhibitors and structural optimisation of protein ligands with therapeutic efficacy.
“Activity-based protein profiling (ABPP) has emerged as a powerful chemoproteomic tool
to characterize the selectivity of enzyme inhibitors on a global scale”. (Source: ACS Med. Chem. Lett. 2011, 43,61,62)
With successful examples of covalent inhibition of the fatty acid amide hydrolase (FAAH) presenting a promising strategy in the treatment of pain and inflammatory disorders, Doug Johnson, Pfizer have previously reported a class of piperidine urea FAAH inhibitors and gone on to develop their clinical candidatePF-04457845.. (Source: ACS Med. Chem. Lett. 2011, 2, 91–96)
SMi Group is delighted to announce that Doug Johnson, Research Fellow at Pfizer will be giving a keynote address at the Advances and Progress in Drug Design conference: Reviving covalent drug design: Discovery of PF-04457845, an irreversible FAAH inhibitor with exquisite selectivity. He will take a closer look at the unique benefits of small molecule covalent drug candidates and activity-based protein profiling, as well as clickable probes to evaluate selectivity of covalent binding.
Furthermore, Gianni Chessari, Director at Astex Pharmaceuticals will give an exclusive session on small molecules in drug design, answering the hot questions – are all protein-fragment interactions favourable? Is the bound conformation a low energy geometry?
Tove Tjogren, Associate Director at AstraZeneca will will take the stage with discovering structure-based drug design within the lipid bilayer. This will take a look at the role of solvent within the protein-lipid interface and ligand efficiency metrics in the context of membrane embedded binding sites.
Other speakers include: Gregg Seigal, Chief Executive Officer, ZoBio; Howard Feldman, Principal Scientist, Chemical Computing Group; Herman van Vlijmen, Senior Director, Janssen; Manuel Francisco Molina-Martin, Research Scientist, Eli Lilly; Jordi Munoz Muriedas, Investigator, GSK and many more.
The Advances and Progress in Drug Design conference program will deliver interactive presentations, case studies and keynote addresses that will enable attendees to understand key developments in protein-based drug design, optimise biophysical tools for compound validation and high resolution screening ad learn unique benefits of small molecule covalent drug design.
Confirmed Sponsors for 2016: Chemical Computing Group, Openeye Scientific Software, NanoTemper Technologies
Those who are interested in attending are advised to register before 30th November to secure the place at the conference and save £200.
For the full event agenda/ to register please visit: www.drug-design.co.uk/prfire
For sponsorship opportunities please contact Alia Malick on +44 (0) 20 7827 6168 or email: firstname.lastname@example.org
For media enquiries please contact Anna Serazetdinova on +44 (0) 20 7827 6180 or email email@example.com
To register for Advances and Progress in Drug Design please contact Matthew Apps on +44 (0) 207 827 6093 or email firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk